Targeting the mTOR pathway in tumor malignancy

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 267-277

  Cheng, Hengmiao ^a   Walls, Marlena ^a   Baxi, Sangita M ^a   Yin, Min Jean ^a  

^a PFIZER INC   (United States)

Author keywords

AKT; Cancer therapeutics; MTOR; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 [1 (1, 4 DIOXASPIRO [4.5] DEC 8 YL) 4 (8 OXA 3 AZABICYCLO [3.2.1] OCT 3 YL) 1H PYRAZOLO [3, 4 D] PYRIMIDIN 6 YL] PHENYL] 3 METHYLUREA; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO [3, 4 D] PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO [3', 2':4, 5] FURO [3, 2 D] PYRIMIDINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL) IMIDAZO [5, 1 F] [1, 2, 4] TRIAZIN 7 YL) CYCLOHEXANECARBOXYLIC ACID; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; APITOLISIB; AZD 2014; AZD 8055; EVEROLIMUS; GDC 0349; GDC 0980; GSK 2126458; INK 128; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 04691502; PF 04979064; PF 05212384; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RAPAMYCIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TEMSIROLIMUS; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; WYE 354; XL 765;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOXIA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84876870807     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313030005     Document Type: Article

References (105)

1. Heitman, J.; Movva, N. R.; Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253, 905-909.
2. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K., Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110 (2), 177-189.
3. Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M., mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110 (2), 163-175.
4. Vander Haar, E.; Lee, S. I.; Bandhakavi, S.; Griffin, T. J.; Kim, D. H., Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007, 9 (3), 316-323.
5. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18 (16), 1926-1945.
6. Lum, J. J.; DeBerardinis, R. J.; Thompson, C. B. Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev. Mol. Cell Biol. 2005, 6 (6), 439-448.
7. Kamada, Y.; Sekito, T.; Ohsumi, Y., Autophagy in yeast: a TORmediated response to nutrient starvation. Curr. Top Microbiol. Immunol. 2004, 279, 73-84.
8. Crino, P. B.; Nathanson, K. L.; Henske, E. P., The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355 (13), 1345-1356.
9. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K. L., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4 (9), 648-657.
10. Manning, B. D.; Logsdon, M. N.; Lipovsky, A. I.; Abbott, D.; Kwiatkowski, D. J.; Cantley, L. C., Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005, 19 (15), 1773-1778.
11. Sancak, Y.; Thoreen, C. C.; Peterson, T. R.; Lindquist, R. A.; Kang, S. A.; Spooner, E.; Carr, S. A.; Sabatini, D. M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25 (6), 903-915.
12. Bhaskar, P. T.; Hay, N., The two TORCs and Akt. Dev Cell 2007, 12 (4), 487-502.
13. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307 (5712), 1098-1101.
14. Guertin, D. A.; Stevens, D. M.; Thoreen, C. C.; Burds, A. A.; Kalaany, N. Y.; Moffat, J.; Brown, M.; Fitzgerald, K. J.; Sabatini, D. M., Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11 (6), 859-871.
15. Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S. Y.; Huang, Q.; Qin, J.; Su, B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127 (1), 125-137.
16. Yang, Q.; Inoki, K.; Ikenoue, T.; Guan, K. L., Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006, 20 (20), 2820-2832.
17. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 2002, 296 (5573), 1655-1657.
18. Mora, A.; Komander, D.; van Aalten, D. M.; Alessi, D. R., PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell. Dev. Biol. 2004, 15 (2), 161-170.
19. Yuan, T. L.; Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27 (41), 5497-5510.
20. Samuels, Y.; Diaz, L. A. Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7 (6), 561-573.
21. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304 (5670), 554.
22. Altomare, D. A.; Testa, J. R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24 (50), 7455-7464.
23. Luo, J.; Manning, B. D.; Cantley, L. C., Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4 (4), 257-262.
24. Creighton, C. J., A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007, 26 (32), 4648-4655.
25. Noh, W. C.; Kim, Y. H.; Kim, M. S.; Koh, J. S.; Kim, H. A.; Moon, N. M.; Paik, N. S., Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat 2008, 110 (3), 477-483.
26. Rojo, F.; Najera, L.; Lirola, J.; Jimenez, J.; Guzman, M.; Sabadell, M. D.; Baselga, J.; Ramony Cajal, S. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 2007, 13 (1), 81-89.
27. van der Hage, J. A.; van den Broek, L. J.; Legrand, C.; Clahsen, P. C.; Bosch, C. J.; Robanus-Maandag, E. C.; van de Velde, C. J.; van de Vijver, M. J., Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in nodenegative premenopausal early breast cancer patients. Br. J. Cancer 2004, 90 (8), 1543-1550.
28. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30 (2), 214-226.
29. Shaw, R. J.; Bardeesy, N.; Manning, B. D.; Lopez, L.; Kosmatka, M.; DePinho, R. A.; Cantley, L. C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6 (1), 91-99.
30. Shaw, R. J.; Kosmatka, M.; Bardeesy, N.; Hurley, R. L.; Witters, L. A.; DePinho, R. A.; Cantley, L. C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 2004, 101 (10), 3329-3335.
31. Carretero, J.; Medina, P. P.; Blanco, R.; Smit, L.; Tang, M.; Roncador, G.; Maestre, L.; Conde, E.; Lopez-Rios, F.; Clevers, H. C.; Sanchez-Cespedes, M. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007, 26 (11), 1616-1625.
32. Gleason, C. E.; Lu, D.; Witters, L. A.; Newgard, C. B.; Birnbaum, M. J. The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 2007, 282 (14), 10341-10351.
33. Warburg, O. On the origin of cancer cells. Science 1956, 123 (3191), 309-314.
34. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324 (5930), 1029-1033.
35. Forcet, C.; Etienne-Manneville, S.; Gaude, H.; Fournier, L.; Debilly, S.; Salmi, M.; Baas, A.; Olschwang, S.; Clevers, H.; Billaud, M. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum. Mol. Genet. 2005, 14 (10), 1283-1292.
36. Giardiello, F. M.; Welsh, S. B.; Hamilton, S. R.; Offerhaus, G. J.; Gittelsohn, A. M.; Booker, S. V.; Krush, A. J.; Yardley, J. H.; Luk, G. D. Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med. 1987, 316 (24), 1511-1514.
37. Ding, L.; Getz, G.; Wheeler, D. A.; Mardis, E. R.; McLellan, M. D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D. M.; Morgan, M. B.; Fulton, L.; Fulton, R. S.; Zhang, Q.; Wendl, M. C.; Lawrence, M. S.; Larson, D. E.; Chen, K.; Dooling, D. J.; Sabo, A.; Hawes, A. C.; Shen, H.; Jhangiani, S. N.; Lewis, L. R.; Hall, O.; Zhu, Y.; Mathew, T.; Ren, Y.; Yao, J.; Scherer, S. E.; Clerc, K.; Metcalf, G. A.; Ng, B.; Milosavljevic, A.; Gonzalez-Garay, M. L.; Osborne, J. R.; Meyer, R.; Shi, X.; Tang, Y.; Koboldt, D. C.; Lin, L.; Abbott, R.; Miner, T. L.; Pohl, C.; Fewell, G.; Haipek, C.; Schmidt, H.; Dunford-Shore, B. H.; Kraja, A.; Crosby, S. D.; Sawyer, C. S.; Vickery, T.; Sander, S.; Robinson, J.; Winckler, W.; Baldwin, J.; Chirieac, L. R.; Dutt, A.; Fennell, T.; Hanna, M.; Johnson, B. E.; Onofrio, R. C.; Thomas, R. K.; Tonon, G.; Weir, B. A.; Zhao, X.; Ziaugra, L.; Zody, M. C.; Giordano, T.; Orringer, M. B.; Roth, J. A.; Spitz, M. R.; Wistuba, II; Ozenberger, B.; Good, P. J.; Chang, A. C.; Beer, D. G.; Watson, M. A.; Ladanyi, M.; Broderick, S.; Yoshizawa, A.; Travis, W. D.; Pao, W.; Province, M. A.; Weinstock, G. M.; Varmus, H. E.; Gabriel, S. B.; Lander, E. S.; Gibbs, R. A.; Meyerson, M.; Wilson, R. K., Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455 (7216), 1069-1075.
38. Sobottka, S. B.; Haase, M.; Fitze, G.; Hahn, M.; Schackert, H. K.; Schackert, G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J. Neurooncol. 2000, 49 (3), 187-195.
39. Wouters, B. G.; Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8 (11), 851-864.
40. Arsham, A. M.; Howell, J. J.; Simon, M. C. A novel hypoxiainducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 2003, 278 (32), 29655-29660.
41. Liu, L.; Cash, T. P.; Jones, R. G.; Keith, B.; Thompson, C. B.; Simon, M. C., Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 2006, 21 (4), 521-531.
42. Brugarolas, J.; Lei, K.; Hurley, R. L.; Manning, B. D.; Reiling, J. H.; Hafen, E.; Witters, L. A.; Ellisen, L. W.; Kaelin, W. G. Jr., Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18 (23), 2893-2904.
43. Reiling, J. H.; Hafen, E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 2004, 18 (23), 2879-2892.
44. Sofer, A.; Lei, K.; Johannessen, C. M.; Ellisen, L. W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell Biol. 2005, 25 (14), 5834-5845.
45. Bernardi, R.; Guernah, I.; Jin, D.; Grisendi, S.; Alimonti, A.; Teruya-Feldstein, J.; Cordon-Cardo, C.; Simon, M. C.; Rafii, S.; Pandolfi, P. P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006, 442 (7104), 779-785.
46. Li, Y.; Wang, Y.; Kim, E.; Beemiller, P.; Wang, C. Y.; Swanson, J.; You, M.; Guan, K. L., Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J. Biol. Chem. 2007, 282 (49), 35803-35813.
47. Nardella, C.; Carracedo, A.; Alimonti, A.; Hobbs, R. M.; Clohessy, J. G.; Chen, Z.; Egia, A.; Fornari, A.; Fiorentino, M.; Loda, M.; Kozma, S. C.; Thomas, G.; Cordon-Cardo, C.; Pandolfi, P. P., Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2009, 2 (55), ra2.
48. Connolly, E.; Braunstein, S.; Formenti, S.; Schneider, R. J., Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell Biol. 2006, 26 (10), 3955-3965.
49. Pugh, C. W.; Ratcliffe, P. J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9 (6), 677-684.
50. Safran, M.; Kaelin, W. G. Jr., HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 2003, 111 (6), 779-783.
51. Land, S. C.; Tee, A. R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 2007, 282 (28), 20534-20543.
52. Hudson, C. C.; Liu, M.; Chiang, G. G.; Otterness, D. M.; Loomis, D. C.; Kaper, F.; Giaccia, A. J.; Abraham, R. T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 2002, 22 (20), 7004-7014.
53. Thomas, G. V.; Tran, C.; Mellinghoff, I. K.; Welsbie, D. S.; Chan, E.; Fueger, B.; Czernin, J.; Sawyers, C. L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12 (1), 122-127.
54. Mizushima, N. Autophagy: process and function. Genes Dev. 2007, 21 (22), 2861-2873.
55. Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J. E.; Luo, S.; Oroz, L. G.; Scaravilli, F.; Easton, D. F.; Duden, R.; O'Kane, C. J.; Rubinsztein, D. C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36 (6), 585-595.
56. Papandreou, I.; Lim, A. L.; Laderoute, K.; Denko, N. C., Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ 2008, 15 (10), 1572-1581.
57. Ikenoue, T.; Inoki, K.; Yang, Q.; Zhou, X.; Guan, K. L., Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008, 27 (14), 1919-1931.
58. Facchinetti, V.; Ouyang, W.; Wei, H.; Soto, N.; Lazorchak, A.; Gould, C.; Lowry, C.; Newton, A. C.; Mao, Y.; Miao, R. Q.; Sessa, W. C.; Qin, J.; Zhang, P.; Su, B.; Jacinto, E., The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008, 27 (14), 1932-1943.
59. Zhang, F.; Zhang, X.; Li, M.; Chen, P.; Zhang, B.; Guo, H.; Cao, W.; Wei, X.; Cao, X.; Hao, X.; Zhang, N., mTOR Complex Component Rictor Interacts with PKC{zeta} and Regulates Cancer Cell Metastasis. Cancer Res. 2010, 70 (22), 9360-9370.
60. Lang, F.; Artunc, F.; Vallon, V., The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr. Opin. Nephrol. Hypertens. 2009, 18 (5), 439-448.
61. Garcia-Martinez, J. M.; Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416 (3), 375-385.
62. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M. A.; Hall, A.; Hall, M. N., Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6 (11), 1122-1128.
63. Gangloff, Y. G.; Mueller, M.; Dann, S. G.; Svoboda, P.; Sticker, M.; Spetz, J. F.; Um, S. H.; Brown, E. J.; Cereghini, S.; Thomas, G.; Kozma, S. C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell Biol. 2004, 24 (21), 9508-9516.
64. Murakami, M.; Ichisaka, T.; Maeda, M.; Oshiro, N.; Hara, K.; Edenhofer, F.; Kiyama, H.; Yonezawa, K.; Yamanaka, S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell Biol. 2004, 24 (15), 6710-6718.
65. Shiota, C.; Woo, J. T.; Lindner, J.; Shelton, K. D.; Magnuson, M. A., Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 2006, 11 (4), 583-589.
66. Bentzinger, C. F.; Romanino, K.; Cloetta, D.; Lin, S.; Mascarenhas, J. B.; Oliveri, F.; Xia, J.; Casanova, E.; Costa, C. F.; Brink, M.; Zorzato, F.; Hall, M. N.; Ruegg, M. A., Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008, 8 (5), 411-424.
67. Cybulski, N.; Polak, P.; Auwerx, J.; Ruegg, M. A.; Hall, M. N., mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA 2009, 106 (24), 9902-9907.
68. Buck, E.; Eyzaguirre, A.; Brown, E.; Petti, F.; McCormack, S.; Haley, J. D.; Iwata, K. K.; Gibson, N. W.; Griffin, G., Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 2006, 5 (11), 2676-2684.
69. Namba, R.; Young, L. J.; Abbey, C. K.; Kim, L.; Damonte, P.; Borowsky, A. D.; Qi, J.; Tepper, C. G.; MacLeod, C. L.; Cardiff, R. D.; Gregg, J. P., Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin. Cancer Res. 2006, 12 (8), 2613-2621.
70. Pencreach, E.; Guerin, E.; Nicolet, C.; Lelong-Rebel, I.; Voegeli, A. C.; Oudet, P.; Larsen, A. K.; Gaub, M. P.; Guenot, D., Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxiainducible factor-1alpha axis. Clin. Cancer Res. 2009, 15 (4), 1297-1307.
71. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11 (14), 5319-5328.
72. Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106 (52), 22299-22304.
73. Chan, S.; Scheulen, M. E.; Johnston, S.; Mross, K.; Cardoso, F.; Dittrich, C.; Eiermann, W.; Hess, D.; Morant, R.; Semiglazov, V.; Borner, M.; Salzberg, M.; Ostapenko, V.; Illiger, H. J.; Behringer, D.; Bardy-Bouxin, N.; Boni, J.; Kong, S.; Cincotta, M.; Moore, L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005, 23 (23), 5314-5322.
74. Del Bufalo, D.; Ciuffreda, L.; Trisciuoglio, D.; Desideri, M.; Cognetti, F.; Zupi, G.; Milella, M., Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66 (11), 5549-5554.
75. Hess, G.; Herbrecht, R.; Romaguera, J.; Verhoef, G.; Crump, M.; Gisselbrecht, C.; Laurell, A.; Offner, F.; Strahs, A.; Berkenblit, A.; Hanushevsky, O.; Clancy, J.; Hewes, B.; Moore, L.; Coiffier, B., Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. J. Clin. Oncol. 2009, 27(23), 3822-3829.
76. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (22), 2271-2281.
77. Guertin, D. A.; Sabatini, D. M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2 (67), pe24.
78. Huang, J.; Manning, B. D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37 (Pt 1), 217-222.
79. O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N., mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66 (3), 1500-8.
80. Zhang, H.; Bajraszewski, N.; Wu, E.; Wang, H.; Moseman, A. P.; Dabora, S. L.; Griffin, J. D.; Kwiatkowski, D. J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 2007, 117 (3), 730-738.
81. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118 (9), 3065-3074.
82. Choo, A. Y.; Yoon, S. O.; Kim, S. G.; Roux, P. P.; Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 2008, 105 (45), 17414-17419.
83. Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; Sabatini, D. M.; Gray, N. S. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284 (12), 8023-8032.
84. Liu, Q.; Chang, J. W.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D. M.; Gray, N. S., Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl) phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53 (19), 7146-7155.
85. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J. E.; Zhang, W. G.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S. K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Abraham, R. T.; Zask, A.; Gibbons, J. J., Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 2010, 70 (2), 621-631.
86. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W. G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D. J.; Cole, D. C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Nowak, P.; Zask, A. Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Res. 2009, 69 (15), 6232-6240.
87. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7 (2), e38.
88. Malagu, K.; Duggan, H.; Menear, K.; Hummersone, M.; Gomez, S.; Bailey, C.; Edwards, P.; Drzewiecki, J.; Leroux, F.; Quesada, M. J.; Hermann, G.; Maine, S.; Molyneaux, C. A.; Le Gall, A.; Pullen, J.; Hickson, I.; Smith, L.; Maguire, S.; Martin, N.; Smith, G.; Pass, M., The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg. Med. Chem. Lett. 2009, 19 (20), 5950-5953.
89. Menear, K. A.; Gomez, S.; Malagu, K.; Bailey, C.; Blackburn, K.; Cockcroft, X. L.; Ewen, S.; Fundo, A.; Le Gall, A.; Hermann, G.; Sebastian, L.; Sunose, M.; Presnot, T.; Torode, E.; Hickson, I.; Martin, N. M.; Smith, G. C.; Pike, K. G. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett. 2009, 19 (20), 5898-5901.
90. Cohen, F.; Bergeron, P.; Blackwood, E.; Bowman, K. K.; Chen, H.; DiPasquale, A. G.; Epler, J. A.; Koehler, M. F.; Lau, K.; Lewis, C.; Liu, L.; Ly, C. Q.; Malek, S.; Nonomiya, J.; Ortwine, D. F.; Pei, Z.; Robarge, K. D.; Sideris, S.; Trinh, L.; Truong, T.; Wu, J.; Zhao, J. and Lyssikatos, J. P. Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine. J. Med. Chem., 2011, 54 (9), 3426-3435.
91. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7 (7), 1851-1863.
92. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P., Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007, 67 (12), 5840-5850.
93. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D. R.; Marx, M. A.; Ninkovic, S.; Sun, S.; Zhang, E., Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med. Chem. Commun. 2010, 1, 139-144.
94. Knight, D. A.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. K.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Dhanak, D., Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010, 1 (1), 39-43.
95. Sutherlin, D. P.; Bao, L.; Berry, M.; Castanedo, G.; Chuckowree, I.; Dotson, J.; Folks, A.; Friedman, L.; Goldsmith, R.; Gunzner, J.; Heffron, T.; Lesnick, J.; Lewis, C.; Mathieu, S.; Murray, J.; Nonomiya, J.; Pang, J.; Pegg, N.; Prior, W. W.; Rouge, L.; Salphati, L.; Sampath, D.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wei, B.; Wiesmann, C.; Wu, P.; Zhu, B. Y.; Olivero, A., Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem. 2011, 54 (21), 7579-7587.
96. Venkatesan, A. M.; Dehnhardt, C. M.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R. T.; Chaudhary, I.; Mansour, T. S., Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 2010, 53 (6), 2636-45.
97. Cheng, H., Li, C., Bailey, S., Baxi, S. M., Goulet, L., Guo, L., Hoffman, J., Jiang, Y., Johnson, T. O., Johnson, T. W., Knighton, D. R., Li, J., Liu, K. K., Liu, Z., Marx, M. A., Walls, M., Wells, P. A., Yin, M. J., Zhu, J., and Zientek, M., Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med. Chem. Lett., 2013, 4 (1), 91-97.
98. Mahoney, C. L.; Choudhury, B.; Davies, H.; Edkins, S.; Greenman, C.; Haaften, G.; Mironenko, T.; Santarius, T.; Stevens, C.; Stratton, M. R.; Futreal, P. A., LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br. J. Cancer 2009, 100 (2), 370-375.
99. Shackelford, D. B.; Vasquez, D. S.; Corbeil, J.; Wu, S.; Leblanc, M.; Wu, C. L.; Vera, D. R.; Shaw, R. J. mTOR and HIF-1alphamediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 2009, 106 (27), 11137-11142.
100. Engelman, J. A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A. R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S. A.; Song, Y.; Chirieac, L. R.; Kaur, R.; Lightbown, A.; Simendinger, J.; Li, T.; Padera, R. F.; Garcia-Echeverria, C.; Weissleder, R.; Mahmood, U.; Cantley, L. C.; Wong, K. K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14 (12), 1351-1356.
101. Mosley, J. D.; Poirier, J. T.; Seachrist, D. D.; Landis, M. D.; Keri, R. A. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol. Cancer Ther. 2007, 6 (8), 2188-2197.
102. Kinkade, C. W.; Castillo-Martin, M.; Puzio-Kuter, A.; Yan, J.; Foster, T. H.; Gao, H.; Sun, Y.; Ouyang, X.; Gerald, W. L.; Cordon-Cardo, C.; Abate-Shen, C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008, 118 (9), 3051-3064.
103. Majumder, P. K.; Febbo, P. G.; Bikoff, R.; Berger, R.; Xue, Q.; McMahon, L. M.; Manola, J.; Brugarolas, J.; McDonnell, T. J.; Golub, T. R.; Loda, M.; Lane, H. A.; Sellers, W. R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10 (6), 594-601.
104. Podsypanina, K.; Lee, R. T.; Politis, C.; Hennessy, I.; Crane, A.; Puc, J.; Neshat, M.; Wang, H.; Yang, L.; Gibbons, J.; Frost, P.; Dreisbach, V.; Blenis, J.; Gaciong, Z.; Fisher, P.; Sawyers, C.; Hedrick-Ellenson, L.; Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc. Natl. Acad. Sci. USA 2001, 98 (18), 10320-10325.
105. Noh, W. C.; Mondesire, W. H.; Peng, J.; Jian, W.; Zhang, H.; Dong, J.; Mills, G. B.; Hung, M. C.; Meric-Bernstam, F. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004, 10 (3), 1013-1023.